



Resource impact template

Resource impact

Published: 18 February 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for previously treated multiple myeloma:

- [Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma](#) (2026) NICE technology appraisal guidance 1149
- [Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma](#) (2026) NICE technology appraisal guidance 1133
- [Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma](#) (2024) NICE technology appraisal guidance 974
- [Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma](#) (2023) NICE technology appraisal guidance 897